Hawkey Nathan M, Zaorsky Nicholas G, Galloway Thomas J
Tulane University School of Medicine, New Orleans, Louisiana, U.S.A.
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, U.S.A.
Laryngoscope. 2016 Jan;126(1):80-5. doi: 10.1002/lary.25444. Epub 2015 Jul 7.
Up to 80% of patients with Parkinson disease and 30% of patients with amyotrophic lateral sclerosis (ALS) suffer from sialorrhea. Patients who fail medical and surgical therapy should be considered for external beam radiation therapy (EBRT). In this study, we conduct a systematic review to determine the dose and techniques used that result in greatest efficacy and lowest toxicity for the administration of EBRT in patients with Parkinson disease or ALS-associated sialorrhea.
This review included 216 patients from four prospective and six retrospective studies published from 1998 to 2014, with ALS or Parkinson disease who were treated with electron or photon EBRT for sialorrhea.
A total of 216 patients were treated with EBRT from 10 studies. The indication for EBRT was failure of alternative medical treatment in all ALS patients. For patients with Parkinson disease, EBRT was the primary mode of treatment in 68% of cases. Overall, 176 (81%) of 216 patients treated with EBRT for sialorrhea reported symptomatic improvement from baseline. The most common target was the inferior two-thirds of the bilateral parotid glands and the entire bilateral submandibular glands. The total number of patients who experienced short-term toxicity was 86 of 216 patients (40%). The total number of patients who experienced long-term toxicity was 24 of 207 (12%).
EBRT is an effective treatment for sialorrhea in patients suffering from ALS or Parkinson disease. Treatment to the bilateral submandibular glands and caudal parotid glands is the most common field arrangement.
高达80%的帕金森病患者和30%的肌萎缩侧索硬化症(ALS)患者患有流涎症。对于药物和手术治疗无效的患者,应考虑进行外照射放疗(EBRT)。在本研究中,我们进行了一项系统评价,以确定在帕金森病或ALS相关性流涎症患者中进行EBRT时,能产生最大疗效且毒性最低的剂量和技术。
本评价纳入了1998年至2014年发表的4项前瞻性研究和6项回顾性研究中的216例ALS或帕金森病患者,这些患者接受了电子或光子EBRT治疗流涎症。
10项研究共纳入216例接受EBRT治疗的患者。所有ALS患者接受EBRT的指征均为替代药物治疗无效。对于帕金森病患者,68%的病例中EBRT是主要治疗方式。总体而言,216例接受EBRT治疗流涎症的患者中有176例(81%)报告症状较基线有所改善。最常见的靶区是双侧腮腺下三分之二和整个双侧颌下腺。216例患者中有86例(40%)出现短期毒性反应。207例患者中有24例(12%)出现长期毒性反应。
EBRT是治疗ALS或帕金森病患者流涎症的有效方法。双侧颌下腺和腮腺尾部是最常见的照射野布局。